We are delighted to announce that Umbra Capital Partners acted as sole financial adviser to Stanley Capital on their acquisition of Noden Pharma from US-listed PDL BioPharma.
In addition to providing strategic financial and debt advisory, we co-invested in the equity alongside Stanley Capital and will be a minority shareholder in the business going forward. This transaction once again validates our modern merchant banking approach — to have skin in the game and be a long-term partner of choice.
Alan Markey, Chief Executive Officer of Noden Pharma DAC, said: “We are delighted to partner with Stanley Capital and look forward to working together to realise our shared goal of building Noden into a leading global specialty pharmaceuticals company. As we start the next chapter in Noden’s growth story, I would like to thank our previous owners PDL BioPharma for all their support over the years and wish them the very best for the future.”
Simon Cottle, Partner at Stanley Capital, said: “The acquisition of Noden is the culmination of years of thematic research into the specialty pharmaceuticals sector, which identified the company as a strong buy and build platform. We look forward to working with Noden’s excellent management team and our industry advisors to build the company into a leading pharma platform, providing essential treatments for patients with unique and difficult to treat conditions.”
Recent news coverage:
Private Equity News – 31 July 2020 – Elisângela Mendonça
Stanley Capital buys Irish Pharma company with a view to consolidate the market.
PR Newswire – 30 July 2020 – PDL BioPharma
PDL BioPharma enters into agreement for the divestiture of the Noden pharmaceutical business to Stanley Capital.
Unquote – 31 July 2020 – Katharine Hidalgo
Stanley Capital has acquired Noden Pharma DAC from PDL BioPharma.